Search

Displaying results 2221 - 2230 of 10000 in total
  1. Drug

    Penbutolol

    go.drugbank.com/drugs/DB01359
    ApprovedInvestigationalWithdrawn

    This binding characteristic of penbutolol is being investigated for its implications in Antidepressant Therapy. … Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker.

  2. Drug

    Colesevelam

    go.drugbank.com/drugs/DB00930
    ApprovedInvestigational

    It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol. … Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood.

  3. Drug

    Methimazole

    go.drugbank.com/drugs/DB00763
    ApprovedInvestigational

    [A184559,A184733,A184694] It was first introduced as an antithyroid agent in 1949[A184502] and is now commonly used in the management of hyperthyroidism, particularly in those for whom more aggressive … Despite documented teratogenic effects in its published labels,[L8336,L8339] the true teratogenicity of methimazole appears to be unclear[A184643,A184757,A184763] and its place in therapy may change in

  4. Drug

    Sonidegib

    go.drugbank.com/drugs/DB09143
    ApprovedInvestigational

    Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.

    Synonyms: N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
  5. Drug

    Elasomeran

    go.drugbank.com/drugs/DB15654
    ApprovedInvestigational

    [L28026] A phase I, open-label, dose-ranging clinical trial (NCT04283461) was initiated in March 2020 in which 45 subjects received two intramuscular doses (on days 1 and 29). … In clinical trials, there were no differences in the safety profiles between younger and older (65 years of age and older) study participants.

  6. Drug

    Allopurinol

    go.drugbank.com/drugs/DB00437
    ApprovedInvestigational

    It was initially approved by the FDA in 1966 [L5674] and is now formulated by several manufacturers [L5677]. … This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals [A175942].

  7. Drug

    Triprolidine

    go.drugbank.com/drugs/DB00427
    Approved

    First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.

    Mixtures: COUGH-EN LINCTUS, COUGH-EN LINCTUS
  8. Drug

    Escitalopram

    go.drugbank.com/drugs/DB01175
    ApprovedInvestigational

    [A185420] It is used to restore serotonergic function in the treatment of depression and anxiety. … escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in

    Products: Escitalopram-GN 10 mg Filmtabletten, Escitalopram-GN 20 mg Filmtabletten
  9. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    [A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163] … The improved ovicidal activity (90-100% _in vitro_) of abemetapir allows for a single administration, in contrast to many other topical treatments, and its novel and relatively non-specific mechanism may

  10. Drug

    Nabumetone

    go.drugbank.com/drugs/DB00461
    Approved

    [label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. … [label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen].

    Mixtures: NuDroxiPAK N-500